Skip to main content
OpenTrials
Completed

NCT Number: NCT05467384

Effect of Amlodipine on the Lipid Profile of Newly Diagnosed Hypertensive Patients

In this study, Amlodipine has been used to study its effects in newly diagnosed hypertensive patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercholesterolemia Cardiovascular Diseases Cholesterol Deposition Dyslipidemias Hyperlipidemias Hypertension Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Vascular Diseases

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

The incidence of hypertension is on the rise in developing countries like Pakistan. Different medications are used to decrease blood pressure with Amlodipine as one of the first-line drugs. It was proposed that due to interaction with calcium and thus luminal cholecystokinin releasing factor; Amlodipine might increase the cholesterol level and thus cause dyslipidemia.

Objective: In this regard, this study was conducted to look into the effects of Amlodipine in newly diagnosed cases of hypertension that had received no medication previously.

Methodology: Experimental study with a healthy control group with the sample size calculated out to be 80, comprising of an equal number of enrolment into case and control groups.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for cases.

  • Newly diagnosed mild to moderate hypertensive. (2) Non-obese individuals. 3) Must not have received antihypertensive treatment previously. 4) Has elevated serum cholesterol levels. Exclusion criteria for cases
  • Any other major illness.

Inclusion criteria

for controls

  • Normal lipid profile.
  • Normotensive (BP < 140/90mmHg). Exclusion criteria for controls
  • Any major illness.

Treatment and study plan

Amlodipine

Drug

5mg/day in two divided doses

Other names: Norvasc

Primary outcomes

  1. Measurement of Blood Glucose Concentration

    Time frame: Four Months

    Measured as per protocols provided by the kit manufacturer.

  2. Measurement of Total Plasma Cholesterol Concentration

    Time frame: Four Months

    Measured as per protocols provided by the kit manufacturer.

  3. Measurement of Plasma Triglyceride Concentration

    Time frame: Four Months

    Measured as per protocols provided by the kit manufacturer.

  4. Measurement of Plasma High Density Lipoproteins Concentration

    Time frame: Four Months

    Measured as per protocols provided by the kit manufacturer.

  5. Measurement of Plasma Low Density Lipoproteins Concentration

    Time frame: Four Months

    Measured as per protocols provided by the kit manufacturer.

Sponsors and collaborators

Lead sponsor

Ayub Teaching Hospital

Other

Collaborators

  • Khyber Medical University Peshawar

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jul 20, 2022
Registry last updated
Jul 20, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.